| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 159, Issue 4 1711-1717, Copyright © 1997 by American Association of Immunologists
ARTICLES |
K Onodera, A Chandraker, M Schaub, TH Stadlbauer, S Korom, R Peach, PS Linsley, MH Sayegh and JW Kupiec-Weglinski
Department of Surgery, Harvard Medical School, Boston, MA 02115, USA.
We tested the effects of blocking CD28-B7 T cell costimulation by using CTLA4Ig in an established transplantation model in which LBNF1 cardiac allografts are rejected in an accelerated manner (<36 h) by LEW rats presensitized with Brown-Norway skin grafts. Treatment with CTLA4Ig with or without donor alloantigen in the sensitization phase (between skin and cardiac engraftment) minimally delayed accelerated rejection. However, adjunctive infusion of CTLA4Ig and donor alloantigen in the effector phase (after cardiac engraftment) resulted in long term graft survival and donor-specific tolerance in 30 to 50% of the recipients. The mutant form of CTLA4Ig, which blocks B7-1 but not B7-2, was ineffective. The tolerant state was accompanied by reduction of cell- mediated (MLR/CTL) responses and depression of humoral (circulating IgM/IgG allo-Abs) alloreactivity in vivo. Hence, the binding of CD28 on T cells to both CD80 and CD86 ligands represents a crucial initial costimulatory step leading to accelerated graft rejection. CTLA4Ig- mediated early blockade of the CD28 signaling pathway combined with transfusion of donor cells in the perioperative period interrupts sensitization and may produce transplantation tolerance. This regimen inhibits T cell costimulation and activation to provide help to CD8+ cytotoxic T and B cells, perhaps, via CTLA4Ig-induced clonal anergy or deletion.
This article has been cited by other articles:
|
|
 |
|
  H. Xu, P. M. Chilton, M. K. Tanner, Y. Huang, C. L. Schanie, M. Dy-Liacco, J. Yan, and S. T. Ildstad Humoral immunity is the dominant barrier for allogeneic bone marrow engraftment in sensitized recipients Blood, November 15, 2006; 108(10): 3611 - 3619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Quezada, K. Bennett, B. R. Blazar, A. Y. Rudensky, S. Sakaguchi, and R. J. Noelle Analysis of the Underlying Cellular Mechanisms of Anti-CD154-Induced Graft Tolerance: The Interplay of Clonal Anergy and Immune Regulation J. Immunol., July 15, 2005; 175(2): 771 - 779. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ito, T. Ueno, M. R. Clarkson, X. Yuan, M. M. Jurewicz, H. Yagita, M. Azuma, A. H. Sharpe, H. Auchincloss Jr, M. H. Sayegh, et al. Analysis of the Role of Negative T Cell Costimulatory Pathways in CD4 and CD8 T Cell-Mediated Alloimmune Responses In Vivo J. Immunol., June 1, 2005; 174(11): 6648 - 6656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Vermeiren, J. L. Ceuppens, M. Van Ghelue, P. Witters, D. Bullens, H. W. Mages, R. A. Kroczek, and S. W. Van Gool Human T Cell Activation by Costimulatory Signal-Deficient Allogeneic Cells Induces Inducible Costimulator-Expressing Anergic T Cells with Regulatory Cell Activity J. Immunol., May 1, 2004; 172(9): 5371 - 5378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Yuan, A. D. Salama, V. Dong, I. Schmitt, N. Najafian, A. Chandraker, H. Akiba, H. Yagita, and M. H. Sayegh The Role of the CD134-CD134 Ligand Costimulatory Pathway in Alloimmune Responses In Vivo J. Immunol., March 15, 2003; 170(6): 2949 - 2955. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhai, L. Meng, F. Gao, R. W. Busuttil, and J. W. Kupiec-Weglinski Allograft Rejection by Primed/Memory CD8+ T Cells Is CD154 Blockade Resistant: Therapeutic Implications for Sensitized Transplant Recipients J. Immunol., October 15, 2002; 169(8): 4667 - 4673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Pantenburg, F. Heinzel, L. Das, P. S. Heeger, and A. Valujskikh T Cells Primed by Leishmania major Infection Cross-React with Alloantigens and Alter the Course of Allograft Rejection J. Immunol., October 1, 2002; 169(7): 3686 - 3693. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. TIKKANEN, K. B. LEMSTROM, and P. K. KOSKINEN Blockade of CD28/B7-2 Costimulation Inhibits Experimental Obliterative Bronchiolitis in Rat Tracheal Allografts . Suppression of Helper T Cell Type1-dominated Immune Response Am. J. Respir. Crit. Care Med., March 1, 2002; 165(5): 724 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Leifeld, C. Trautwein, F. L. Dumoulin, M. P. Manns, T. Sauerbruch, and U. Spengler Enhanced Expression of CD80 (B7-1), CD86 (B7-2), and CD40 and Their Ligands CD28 and CD154 in Fulminant Hepatic Failure Am. J. Pathol., June 1, 1999; 154(6): 1711 - 1720. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Saverino, C. Tenca, D. Zarcone, A. Merlo, A. M. Megiovanni, M. T. Valle, F. Manca, C. E. Grossi, and E. Ciccone CTLA-4 (CD152) Inhibits the Specific Lysis Mediated by Human Cytolytic T Lymphocytes in a Clonally Distributed Fashion J. Immunol., January 15, 1999; 162(2): 651 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Onodera, H.-D. Volk, T. Ritter, and J. W. Kupiec-Weglinski Thymus Requirement and Antigen Dependency in the ""Infectious"" Tolerance Pathway in Transplant Recipients J. Immunol., June 15, 1998; 160(12): 5765 - 5772. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
